146 related articles for article (PubMed ID: 38041094)
1. Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial.
Krass I; Twigg MJ; Mitchell B; Wilson F; Mohebbi M; Trinder P; Shih STF; Carter R; Versace VL; McNamara K
BMC Health Serv Res; 2023 Dec; 23(1):1337. PubMed ID: 38041094
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy diabetes screening trial (PDST): Outcomes of a national clustered RCT comparing three screening methods for undiagnosed type 2 diabetes (T2DM) in community pharmacy.
Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Mc Namara KP
Diabetes Res Clin Pract; 2023 Mar; 197():110566. PubMed ID: 36738834
[TBL] [Abstract][Full Text] [Related]
3. Pharmacy Diabetes Screening Trial: protocol for a pragmatic cluster-randomised controlled trial to compare three screening methods for undiagnosed type 2 diabetes in Australian community pharmacy.
Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Namara KM
BMJ Open; 2017 Dec; 7(12):e017725. PubMed ID: 29284715
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and cardiovascular disease risk screening model in community pharmacies in a developing primary healthcare system: a feasibility study.
Alzubaidi HT; Chandir S; Hasan S; McNamara K; Cox R; Krass I
BMJ Open; 2019 Nov; 9(11):e031246. PubMed ID: 31712336
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment and HbA1c measurement in Norwegian community pharmacies to identify people with undiagnosed type 2 diabetes - A feasibility study.
Risøy AJ; Kjome RLS; Sandberg S; Sølvik UØ
PLoS One; 2018; 13(2):e0191316. PubMed ID: 29474501
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two methods for assessing diabetes risk in a pharmacy setting in Australia.
Kilkenny MF; Johnson R; Andrew NE; Purvis T; Hicks A; Colagiuri S; Cadilhac DA
BMC Public Health; 2014 Nov; 14():1227. PubMed ID: 25427845
[TBL] [Abstract][Full Text] [Related]
7. Involving the public and other stakeholders in development and evaluation of a community pharmacy alcohol screening and brief advice service.
Krska J; Mackridge AJ
Public Health; 2014 Apr; 128(4):309-16. PubMed ID: 24713598
[TBL] [Abstract][Full Text] [Related]
8. Feasibility, accessibility and acceptability a pharmacist-led ear health intervention at rural community pharmacies (LISTEN UP): a mixed-methods study in Queensland, Australia.
Taylor S; Cairns A; Glass BD
BMJ Open; 2022 Apr; 12(4):e057011. PubMed ID: 35365533
[TBL] [Abstract][Full Text] [Related]
9. Community pharmacy integration within the primary care pathway for people with long-term conditions: a focus group study of patients', pharmacists' and GPs' experiences and expectations.
Hindi AMK; Schafheutle EI; Jacobs S
BMC Fam Pract; 2019 Feb; 20(1):26. PubMed ID: 30736732
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of a collaborative diabetes screening campaign between community pharmacies and general practitioners.
Murteira R; Cary M; Galante H; Romano S; Guerreiro JP; Rodrigues AT
Prim Care Diabetes; 2023 Aug; 17(4):314-320. PubMed ID: 37156696
[TBL] [Abstract][Full Text] [Related]
11. Implementation of diabetes screening in community pharmacy - factors influencing successful implementation.
Siu AHY; Krass I; Mitchell B; McNamara K
Res Social Adm Pharm; 2021 Sep; 17(9):1606-1613. PubMed ID: 33414090
[TBL] [Abstract][Full Text] [Related]
12. Screening for type 2 diabetes with random finger-prick glucose and bedside HbA1c in an Australian emergency department.
Jelinek GA; Weiland TJ; Moore G; Tan G; Maslin M; Bowman K; Ward G; O'Dea K
Emerg Med Australas; 2010 Oct; 22(5):427-34. PubMed ID: 21040483
[TBL] [Abstract][Full Text] [Related]
13. Diabetes risk assessments and HbA1c-measurements in community pharmacies.
Risøy AJ; Kjome RLS; Sandberg S; Sølvik UØ
Int J Pharm Pract; 2023 Sep; 31(5):512-519. PubMed ID: 37527496
[TBL] [Abstract][Full Text] [Related]
14. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy.
Krass I; Mitchell B; Clarke P; Brillant M; Dienaar R; Hughes J; Lau P; Peterson G; Stewart K; Taylor S; Wilkinson J; Armour C
Diabetes Res Clin Pract; 2007 Mar; 75(3):339-47. PubMed ID: 16884811
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of a novel pharmacy screening intervention to address the burden of type 2 diabetes and cardiovascular disease in an Arabic-speaking country.
Alzubaidi H; Hasan S; Saidawi W; Mc Namara K; Chandir S; Krass I
Diabet Med; 2021 Aug; 38(8):e14598. PubMed ID: 33969536
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a chronic kidney disease risk assessment service in community pharmacies.
Gheewala PA; Peterson GM; Zaidi STR; Jose MD; Castelino RL
Nephrology (Carlton); 2019 Mar; 24(3):301-307. PubMed ID: 29493051
[TBL] [Abstract][Full Text] [Related]
17. Using the AUSDRISK score to screen for pre-diabetes and diabetes in GP practices: a case-finding approach.
Fleming K; Weaver N; Peel R; Hure A; McEvoy M; Holliday E; Parsons M; Acharya S; Luu J; Wiggers J; Rissel C; Ranasinghe P; Jayawardena R; Samman S; Attia J
Aust N Z J Public Health; 2022 Apr; 46(2):203-207. PubMed ID: 34762354
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of community pharmacy-based services for type-2 diabetes in an Indonesian setting: pharmacist survey.
Wibowo Y; Parsons R; Sunderland B; Hughes J
Int J Clin Pharm; 2015 Oct; 37(5):873-82. PubMed ID: 25986291
[TBL] [Abstract][Full Text] [Related]
19. The impact of point of care testing on diabetes services along Victoria's Mallee Track: results of a community-based diabetes risk assessment and management program.
Shephard MD; Mazzachi BC; Shephard AK; McLaughlin KJ; Denner B; Barnes G
Rural Remote Health; 2005; 5(3):371. PubMed ID: 16026194
[TBL] [Abstract][Full Text] [Related]
20. Building capacity in primary care: the implementation of a novel 'Pharmacy First' scheme for the management of UTI, impetigo and COPD exacerbation.
Stewart F; Caldwell G; Cassells K; Burton J; Watson A
Prim Health Care Res Dev; 2018 Nov; 19(6):531-541. PubMed ID: 29362007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
